TTEN·K/calls
Pinned
  • The Brief
  • Congress
  • Screener
  • Markets
  • The Brief
  • Signal Confluence
  • The Flip Side
  • Markets
  • Calendar
  • Coverage
  • Screener
  • Discover
  • Smart Money
  • Congress
  • Insiders
  • IPOs
  • ETF Holdings
  • 13F Funds
  • Events
  • Filings
  • News
  • Trending
  • Groups
  • Data catalog
  • Research
  • Education
  • Options Plays
  • Options Calculator
  • Leaderboards
  • Compare
  • Portfolio
  • Strategies
  • Track
  • Pricing
  • API
  • Newsletter
  • Follow the calls
  • Feedback
  • Account
Go ProUpgrade →
TTEN·K/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Telegram ↗X ↗Bluesky ↗Follow the calls →

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

MethodologyDisclosuresTermsPrivacy

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

← New search
Home›Coverage›TVGNW
On this page
OverviewFinancialsValuationQualitySmart moneyTimelineFilings

TVGNWTevogen Bio Holdings Inc.

Hold
$0.06
▲ 0.00%
Rating
Hold
Quality
F
Valuation
Fair value
Filings
Flagged
How to read this →
HoldConservative balance sheet (liabilities/equity -1.53x).Liabilities / equity -1.53xFull call ↓
$0.06▼ -30.73%
over 1Y
L $0.03H $0.08
Our buy Our hold Our sell Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today
+0.0%
1W
-3.0%
1M
+12.5%
3M
+69.2%
YTD
+31.3%
1Y
-30.7%
OverviewFinancialsValuationQualitySmart moneyTimelineFilings
Hold
Conviction
Horizon
Medium (3–12mo)

Conservative balance sheet (liabilities/equity -1.53x).

Liabilities / equity -1.53x · latest

This call stands until the filings change it — the engine re-rates on new 10-K/10-Q/8-K facts, never on price moves. Hit Watch above to follow TVGNW (Pro alerts fire the moment a rating flips), or catch every change in Saturday’s Flip Side. How to read a call

Tevogen Bio Holdings Inc. shows limited reported revenue.

Supporting the case: conservative balance sheet (liabilities/equity -1.53x).

Is TVGNW a buy? The one-page verdict, explained →

The options angle

model · matches our verdict
Covered call~65d expiry
  • Long 100 shares @ ~0.06
  • Short call 0.5 @ ~0.00 est
debit $6max +$44max −$5BE 0.06

HOLD means own it, don't chase it — harvesting premium against the position matches the verdict.

Open in the calculator →
Browse all model plays →

Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.

Financialsannual, by fiscal year

Line itemFY22FY23FY24FY25
Revenue————
Gross profit————
Operating income—-$8.84M-$53.6M-$26.1M
Net income$4.41M-$60.5M-$13.7M-$26.3M
Diluted EPS—-$2.44-$3.50-$8.08
Net margin————

10-year statements — income, cash flow, balance sheet & CSV export →

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$229K
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-11472.4%
FCF yield-5411.1%

Quality & risk

ROIC (est.)—
Free cash flow-$12.4M
Total debt$0.00
Net cash$0.00
Piotroski F-Score2/6

Capital returns

Buyback yield149754.4%
Dividend yield (est.)—
Shareholder yield149754.4%
Shares Δ YoY-97.7%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Disclosure timelineSEC · 8-Ks + reports

Red flag in recent filings — restated periodic report (2026-04-30). Worth a closer look.
  1. S-3 Shelf registration (potential raise)2026-06-12
  2. 10-Q Quarterly report2026-05-15
  3. 10-K/A Restated periodic report2026-04-30
  4. 8-K Listing-standards notice2026-04-22
  5. 10-K Annual report2026-03-31
  6. 8-K Other event2026-03-25
  7. 8-K Material event2026-03-04
  8. 8-K Officer / director change2026-02-25
  9. 8-K Reg FD disclosure2026-01-30

Recent filings

all on EDGAR ↗
SCHEDULE 13D/AFiling2026-07-14open ↗4Period ending 2026-07-102026-07-10open ↗4Period ending 2026-07-102026-07-10open ↗4Period ending 2026-07-102026-07-10open ↗4Period ending 2026-07-102026-07-10open ↗4Period ending 2026-07-102026-07-10open ↗4Period ending 2026-07-102026-07-10open ↗4Period ending 2026-07-102026-07-10open ↗S-8Filing2026-07-10open ↗424B3Filing2026-06-26open ↗EFFECTFiling2026-06-25open ↗S-3Filing2026-06-12open ↗

Quality score

F
ValueGrowthProfitHealthMom.
Value—
GrowthF
Profitability—
Financial healthF
MomentumC+
  • ✗Profitable (positive net income)
  • ✓Liabilities below 2× equity
0.0352-week0.07
Revenue
—
Net margin
—
ROE
—
P/E
—

SEC fundamentals · FY 2025

'22'23'24'25

■ revenue · ■ net income, by fiscal year

Net income-$26.3M-91.4%
Operating income-$26.1M+51.2%
Diluted EPS-$8.08-130.9%
Cash & equivalents$0.00
Total assets$4.38M+26.6%
Total liabilities$12.6M+24.5%
Stockholders' equity-$8.23M-23.4%
L/E: -1.53x

Frequently asked

Is Tevogen Bio Holdings Inc. (TVGNW) a buy?
TVGNW currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity -1.53x).
What is Tevogen Bio Holdings Inc.'s quality score?
TVGNW scores 30.98760330578512/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

New filings change verdicts

The daily Brief delivers our freshest calls, rating flips and the filings behind them — every morning, free.

Sources: SEC EDGAR (CIK 0001860871, latest 10-Q filed 2026-05-15) · EODHD · as of 7/15/2026, 7:30:58 PM.

›About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice

Rule-based analysis, generated automatically from SEC filing data.

Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 15, 2026, 3:30 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Intraday
NVDA$209.23▼1.22%AAPL$327.82▲4.12%GOOGL$370.03▲2.93%GOOG$368.77▲3.20%MSFT$396.34▲2.96%AMZN$254.96▲3.02%TSM$417.95▼0.58%AVGO$391.94▲0.73%SPCX$134.77▼0.97%META$673.73▲1.92%TSLA$398.30▲0.54%MU$906.76▼7.77%BRK-A$734,704.78▼0.31%BRK-B$490.10▼0.20%LLY$1,146.65▼0.51%JPM$347.08▲1.22%WMT$113.86▲0.14%AMD$527.56▼3.75%ASML$1,790.43▲0.83%V$358.63▲0.73%JNJ$249.64▼1.66%XOM$143.08▼1.39%INTC$101.96▼5.38%MA$537.58▼0.08%AMAT$574.51▼3.56%CSCO$111.65▼4.65%LRCX$329.07▼4.92%ABBV$246.99▲0.90%CAT$903.41▼3.21%BAC$61.49▲1.44%
NVDA$209.23▼1.22%AAPL$327.82▲4.12%GOOGL$370.03▲2.93%GOOG$368.77▲3.20%MSFT$396.34▲2.96%AMZN$254.96▲3.02%TSM$417.95▼0.58%AVGO$391.94▲0.73%SPCX$134.77▼0.97%META$673.73▲1.92%TSLA$398.30▲0.54%MU$906.76▼7.77%BRK-A$734,704.78▼0.31%BRK-B$490.10▼0.20%LLY$1,146.65▼0.51%JPM$347.08▲1.22%WMT$113.86▲0.14%AMD$527.56▼3.75%ASML$1,790.43▲0.83%V$358.63▲0.73%JNJ$249.64▼1.66%XOM$143.08▼1.39%INTC$101.96▼5.38%MA$537.58▼0.08%AMAT$574.51▼3.56%CSCO$111.65▼4.65%LRCX$329.07▼4.92%ABBV$246.99▲0.90%CAT$903.41▼3.21%BAC$61.49▲1.44%
Intraday
NVDA$209.23▼1.22%AAPL$327.82▲4.12%GOOGL$370.03▲2.93%GOOG$368.77▲3.20%MSFT$396.34▲2.96%AMZN$254.96▲3.02%TSM$417.95▼0.58%AVGO$391.94▲0.73%SPCX$134.77▼0.97%META$673.73▲1.92%TSLA$398.30▲0.54%MU$906.76▼7.77%BRK-A$734,704.78▼0.31%BRK-B$490.10▼0.20%LLY$1,146.65▼0.51%JPM$347.08▲1.22%WMT$113.86▲0.14%AMD$527.56▼3.75%ASML$1,790.43▲0.83%V$358.63▲0.73%JNJ$249.64▼1.66%XOM$143.08▼1.39%INTC$101.96▼5.38%MA$537.58▼0.08%AMAT$574.51▼3.56%CSCO$111.65▼4.65%LRCX$329.07▼4.92%ABBV$246.99▲0.90%CAT$903.41▼3.21%BAC$61.49▲1.44%
NVDA$209.23▼1.22%AAPL$327.82▲4.12%GOOGL$370.03▲2.93%GOOG$368.77▲3.20%MSFT$396.34▲2.96%AMZN$254.96▲3.02%TSM$417.95▼0.58%AVGO$391.94▲0.73%SPCX$134.77▼0.97%META$673.73▲1.92%TSLA$398.30▲0.54%MU$906.76▼7.77%BRK-A$734,704.78▼0.31%BRK-B$490.10▼0.20%LLY$1,146.65▼0.51%JPM$347.08▲1.22%WMT$113.86▲0.14%AMD$527.56▼3.75%ASML$1,790.43▲0.83%V$358.63▲0.73%JNJ$249.64▼1.66%XOM$143.08▼1.39%INTC$101.96▼5.38%MA$537.58▼0.08%AMAT$574.51▼3.56%CSCO$111.65▼4.65%LRCX$329.07▼4.92%ABBV$246.99▲0.90%CAT$903.41▼3.21%BAC$61.49▲1.44%
Smart money○○○→

Smart moneyinsiders · Congress · funds

○○○

Disclosed smart-money activity in TVGNW, but no clear buy consensus.

—
Corporate insiders
No recent Form 4 activity
Form 4
—
Congress
No disclosed trades
STOCK Act · ~45d lag
—
Institutions
1 tracked fund hold · $3.90K
13F · quarterly

Different disclosure clocks — Form 4s file within days, Congress PTRs lag up to ~45 days, and 13F holdings are a quarterly snapshot (up to ~4.5 months old). A disclosed-accumulation view, not live correlation.

Insider activityForm 4 · SEC

all insiders →
2026-07-10
Sordillo Victor J.
Director
Award
40.0K
2026-07-10
Saadi Ryan H.
Chief Executive Officer
Award
1.22M
2026-07-10
PODLOGAR SUSAN M
Director
Award
40.0K
2026-07-10
Patton Curtis L.
Director
Award
40.0K
2026-07-10
Goh Keow Lin
Director
Award
40.0K
2026-07-10
Feike Jeffrey L.
Director
Award
40.0K
2026-07-10
Desai Kirti
Chief Financial Officer
Award
40.0K
2026-03-13
Flomenberg Neal
See Remarks
Selldiscretionary
501.00 @ $6.40$3.21K
2026-03-11
Flomenberg Neal
See Remarks
Selldiscretionary
452.00 @ $7.26$3.28K
2026-03-10
Flomenberg Neal
See Remarks
Selldiscretionary
19.00 @ $7.75$147.25

Held by tracked fundsForm 13F · SEC · quarterly

Sculptor Capital124K sh$3.90K

As of each fund’s latest quarterly 13F — a delayed snapshot, not a live position. All tracked funds →

Fails-to-deliver

SEC · settled 2026-06-30
6.35Kshares failed to deliver0.2× median

TVGNW fails-to-deliver history — every published settlement day →

Aggregate CNS settlement fails on the latest published day, vs this name’s trailing median. From SEC fails-to-deliver data (published twice monthly) — a settlement metric, not short interest.

Earnings history

beat/miss · move
2024-04-26—▼ -4.55%8-K ↗

Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.

Recent news

market news →
Tevogen Regains Compliance with Nasdaq Minimum Bid Price RequirementBullish
finance.yahoo.com· 2026-03-25
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)Bullish
finance.yahoo.com· 2026-03-18
Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data ExpansionBullish
finance.yahoo.com· 2025-09-25
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in BostonBullish
finance.yahoo.com· 2025-09-10
Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation DisclosureBullish
finance.yahoo.com· 2025-08-27
Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained PositionsBullish
finance.yahoo.com· 2025-08-25

Vs tracked universe

compare →

1178 tracked peers · median

TENK Score31 vs 67
Revenue growth— vs 7.6%
Net margin— vs 10.0%
Return on equity— vs 12.0%
P/E— vs 26.4